- Home
- CIFRW vs ICUCW Comparison
CIFRW vs ICUCW Comparison
Compare CIFRW & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFRW
- ICUCW
- Stock Information
- Founded
- CIFRW 2020
- ICUCW N/A
- Country
- CIFRW United States
- ICUCW United States
- Employees
- CIFRW 43
- ICUCW 18
- Industry
- CIFRW Investment Bankers/Brokers/Service
- ICUCW Biotechnology: Pharmaceutical Preparations
- Sector
- CIFRW Finance
- ICUCW Health Care
- Exchange
- CIFRW Nasdaq
- ICUCW Nasdaq
- Market Cap
- CIFRW N/A
- ICUCW N/A
- IPO Year
- CIFRW N/A
- ICUCW 2021
- Fundamental
- Price
- CIFRW $9.50
- ICUCW $0.04
- Analyst Decision
- CIFRW
- ICUCW
- Analyst Count
- CIFRW 0
- ICUCW 0
- Target Price
- CIFRW N/A
- ICUCW N/A
- AVG Volume (30 Days)
- CIFRW 67.9K
- ICUCW N/A
- Earning Date
- CIFRW 02-25-2025
- ICUCW N/A
- Dividend Yield
- CIFRW N/A
- ICUCW N/A
- EPS Growth
- CIFRW N/A
- ICUCW N/A
- EPS
- CIFRW N/A
- ICUCW N/A
- Revenue
- CIFRW $152,466,000.00
- ICUCW N/A
- Revenue This Year
- CIFRW N/A
- ICUCW N/A
- Revenue Next Year
- CIFRW N/A
- ICUCW N/A
- P/E Ratio
- CIFRW N/A
- ICUCW N/A
- Revenue Growth
- CIFRW 76.34
- ICUCW N/A
- 52 Week Low
- CIFRW $1.58
- ICUCW N/A
- 52 Week High
- CIFRW $1.69
- ICUCW N/A
- Technical
- Relative Strength Index (RSI)
- CIFRW 66.45
- ICUCW 52.56
- Support Level
- CIFRW $6.93
- ICUCW $0.03
- Resistance Level
- CIFRW $11.79
- ICUCW $0.03
- Average True Range (ATR)
- CIFRW 1.51
- ICUCW 0.01
- MACD
- CIFRW 0.23
- ICUCW 0.00
- Stochastic Oscillator
- CIFRW 70.53
- ICUCW 62.99
About CIFRW Cipher Mining Inc. Warrant
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About ICUCW SeaStar Medical Holding Corporation Warrant
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.